RayKnowChina Research Map
Shortlist0

RecruitingAnti-NMDA receptor encephalitisPhase 2

Registered title, quoted from ClinicalTrials.gov

Efgartigimod in Anti-NMDA Receptor Encephalitis.

An open trial on anti-NMDA receptor encephalitis, registered on ClinicalTrials.gov. Led by Beijing Tongren Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07822776, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Study subjects had received at least 3 days of glucocorticoid therapy at a dose of 500-1000 mg MP daily within 2 weeks prior to enrollment (baseline visit). They had transitioned to oral corticosteroid therapy and stable doses of non-steroidal immunosuppressive agents (NISIT) (limited to relapsed patients), and had not received IVIG or plasma exchange.

    Inclusion criterion 18

    Presence of any untreated teratoma or thymoma at baseline visit. Detection of teratoma or thymoma prior to or during the screening period is permitted if the disease is considered cured following treatment (typically surgical resection) within 1 week before baseline.

    Exclusion criterion 1

    Received IVIG or PE therapy within 2 weeks prior to screening.

    Exclusion criterion 3

  3. For women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose of Efgartigimod.

    Inclusion criterion 19

    Pregnancy

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07822776, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years old, male or female;
  • Diagnosed as anti-NMDAR encephalitis, diagnostic criteria as follows:
  • At least one of the following six major symptoms:
  • Abnormal (mental) behavior or cognitive dysfunction
  • Speech dysfunction (verbal urgency, hypospeech, mutism)
  • Seizures
  • Movement disorders, dyskinesias, or postural rigidity/abnormalities
  • Decreased level of consciousness
  • Autonomic dysfunction or central hypoventilation in the presence of one or more of the six major symptoms;
  • Positive anti-NMDAR IgG antibody: Diagnosis should be based on CSF antibody positivity using CBA. If only serum samples are available for testing, a positive CBA result must be supplemented with TBA on cultured neurons for definitive confirmation. Serum positivity at low titers (1:10) is not diagnostically significant.

c.Reasonable exclusion of other etiologies.

  • Patients with newly diagnosed or relapsed anti-NMDAR encephalitis who scored ≥2 on the mRS (5 patients each with mRS scores of 2-5);
  • Newly diagnosed patients must not have received any prior immunosuppressive therapy.
  • For relapsed patients:
  • For subjects receiving rituximab, treatment must have commenced at least 2 months prior to screening, with the final dose administered no less than 4 weeks before randomization, and no improvement in mRS score within the 4 weeks preceding randomization.
  • For subjects receiving other immunosuppressive agents (i.e., mycophenolate mofetil, cyclophosphamide, or azathioprine), treatment must have been ongoing for at least 2 months prior to screening, the dose must have been stable for at least 4 weeks prior to screening, and there must have been no improvement in the mRS score within 4 weeks prior to randomization.
  • For subjects receiving oral corticosteroids, those receiving a stable daily dose of ≥20 mg of prednisolone (or its equivalent) with no increase in steroid dosage within 4 weeks prior to screening, and no improvement in mRS score within 4 weeks prior to randomization.
  • For subjects receiving repeated courses (pulse therapy) of acute first-line therapy, treatment must be completed >2 weeks prior to randomization (baseline visit).
  • Study subjects had received at least 3 days of glucocorticoid therapy at a dose of 500-1000 mg MP daily within 2 weeks prior to enrollment (baseline visit). They had transitioned to oral corticosteroid therapy and stable doses of non-steroidal immunosuppressive agents (NISIT) (limited to relapsed patients), and had not received IVIG or plasma exchange.
  • For women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last dose of Efgartigimod.
  • Ability to sign an informed consent form, which includes agreeing to comply with the requirements and restrictions outlined in the informed consent form and this protocol.

Exclusion Criteria:

Subjects should be excluded from the study if they meet any of the following criteria:

  • Presence of any untreated teratoma or thymoma at baseline visit. Detection of teratoma or thymoma prior to or during the screening period is permitted if the disease is considered cured following treatment (typically surgical resection) within 1 week before baseline.
  • Known allergy to any component of the study drug or any other anti-FcRn drug.
  • Received IVIG or PE therapy within 2 weeks prior to screening.
  • Research participants with clinically significant active infections (including unresolved or inadequately treated infections) as assessed by the investigator.
  • Malignancies requiring chemotherapy.
  • Total IgG level ≤6 g/L in study subjects during screening visits.
  • Pregnancy
  • Patients with severe underlying conditions such as cardiac insufficiency, arrhythmia, or coagulation disorders.

Quoted from ClinicalTrials.gov, NCT07822776, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07822776, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07822776